将多基因风险纳入莱斯特风险评估评分,预测 2 型糖尿病的 10 年风险

IF 4.3 Q1 ENDOCRINOLOGY & METABOLISM Diabetes & Metabolic Syndrome-Clinical Research & Reviews Pub Date : 2024-04-01 DOI:10.1016/j.dsx.2024.102996
Xiaonan Liu , Thomas J. Littlejohns , Jelena Bešević , Fiona Bragg , Lei Clifton , Jennifer A. Collister , Eirini Trichia , Laura J. Gray , Kamlesh Khunti , David J. Hunter
{"title":"将多基因风险纳入莱斯特风险评估评分,预测 2 型糖尿病的 10 年风险","authors":"Xiaonan Liu ,&nbsp;Thomas J. Littlejohns ,&nbsp;Jelena Bešević ,&nbsp;Fiona Bragg ,&nbsp;Lei Clifton ,&nbsp;Jennifer A. Collister ,&nbsp;Eirini Trichia ,&nbsp;Laura J. Gray ,&nbsp;Kamlesh Khunti ,&nbsp;David J. Hunter","doi":"10.1016/j.dsx.2024.102996","DOIUrl":null,"url":null,"abstract":"<div><h3>Aims</h3><p>We evaluated whether incorporating information on ethnic background and polygenic risk enhanced the Leicester Risk Assessment (LRA<em>)</em> score for predicting 10-year risk of type 2 diabetes.</p></div><div><h3>Methods</h3><p>The sample included 202,529 UK Biobank participants aged 40–69 years. We computed the <em>LRA score</em>, and developed two new risk scores using training data (80% sample): <em>LRArev</em>, which incorporated additional information on ethnic background, and <em>LRAprs</em>, which incorporated polygenic risk for type 2 diabetes. We assessed discriminative and reclassification performance in a test set (20% sample). Type 2 diabetes was ascertained using primary care, hospital inpatient and death registry records.</p></div><div><h3>Results</h3><p>Over 10 years, 7,476 participants developed type 2 diabetes. The Harrell's C indexes were 0.796 (95% Confidence Interval [CI] 0.785, 0.806), 0.802 (95% CI 0.792, 0.813), and 0.829 (95% CI 0.820, 0.839) for the <em>LRA</em>, <em>LRArev</em> and <em>LRAprs</em> scores, respectively. The <em>LRAprs</em> score significantly improved the overall reclassification compared to the <em>LRA</em> (net reclassification index [NRI] = 0.033, 95% CI 0.015, 0.049) and <em>LRArev</em> (NRI = 0.040, 95% CI 0.024, 0.055) <em>scores</em>.</p></div><div><h3>Conclusions</h3><p>Polygenic risk moderately improved the performance of the existing <em>LRA score</em> for 10-year risk prediction of type 2 diabetes.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 4","pages":"Article 102996"},"PeriodicalIF":4.3000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1871402124000572/pdfft?md5=9424f3ac9af33735a2cee24ff4916bd4&pid=1-s2.0-S1871402124000572-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Incorporating polygenic risk into the Leicester Risk Assessment score for 10-year risk prediction of type 2 diabetes\",\"authors\":\"Xiaonan Liu ,&nbsp;Thomas J. Littlejohns ,&nbsp;Jelena Bešević ,&nbsp;Fiona Bragg ,&nbsp;Lei Clifton ,&nbsp;Jennifer A. Collister ,&nbsp;Eirini Trichia ,&nbsp;Laura J. Gray ,&nbsp;Kamlesh Khunti ,&nbsp;David J. Hunter\",\"doi\":\"10.1016/j.dsx.2024.102996\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Aims</h3><p>We evaluated whether incorporating information on ethnic background and polygenic risk enhanced the Leicester Risk Assessment (LRA<em>)</em> score for predicting 10-year risk of type 2 diabetes.</p></div><div><h3>Methods</h3><p>The sample included 202,529 UK Biobank participants aged 40–69 years. We computed the <em>LRA score</em>, and developed two new risk scores using training data (80% sample): <em>LRArev</em>, which incorporated additional information on ethnic background, and <em>LRAprs</em>, which incorporated polygenic risk for type 2 diabetes. We assessed discriminative and reclassification performance in a test set (20% sample). Type 2 diabetes was ascertained using primary care, hospital inpatient and death registry records.</p></div><div><h3>Results</h3><p>Over 10 years, 7,476 participants developed type 2 diabetes. The Harrell's C indexes were 0.796 (95% Confidence Interval [CI] 0.785, 0.806), 0.802 (95% CI 0.792, 0.813), and 0.829 (95% CI 0.820, 0.839) for the <em>LRA</em>, <em>LRArev</em> and <em>LRAprs</em> scores, respectively. The <em>LRAprs</em> score significantly improved the overall reclassification compared to the <em>LRA</em> (net reclassification index [NRI] = 0.033, 95% CI 0.015, 0.049) and <em>LRArev</em> (NRI = 0.040, 95% CI 0.024, 0.055) <em>scores</em>.</p></div><div><h3>Conclusions</h3><p>Polygenic risk moderately improved the performance of the existing <em>LRA score</em> for 10-year risk prediction of type 2 diabetes.</p></div>\",\"PeriodicalId\":48252,\"journal\":{\"name\":\"Diabetes & Metabolic Syndrome-Clinical Research & Reviews\",\"volume\":\"18 4\",\"pages\":\"Article 102996\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1871402124000572/pdfft?md5=9424f3ac9af33735a2cee24ff4916bd4&pid=1-s2.0-S1871402124000572-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes & Metabolic Syndrome-Clinical Research & Reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1871402124000572\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1871402124000572","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

目的我们评估了纳入种族背景和多基因风险信息是否会提高莱斯特风险评估(LRA)预测 2 型糖尿病 10 年风险的得分。方法样本包括 202,529 名年龄在 40-69 岁之间的英国生物库参与者。我们计算了 LRA 评分,并利用训练数据(80% 的样本)开发了两种新的风险评分:LRArev 包含种族背景的附加信息,LRAprs 包含 2 型糖尿病的多基因风险。我们评估了测试集(20% 样本)的判别和再分类性能。2 型糖尿病是通过初级保健、医院住院病人和死亡登记记录确定的。LRA、LRArev 和 LRAprs 评分的哈雷尔 C 指数分别为 0.796(95% 置信区间 [CI] 0.785,0.806)、0.802(95% CI 0.792,0.813)和 0.829(95% CI 0.820,0.839)。与 LRA(净再分类指数 [NRI] = 0.033,95% CI 0.015,0.049)和 LRArev(净再分类指数 [NRI] = 0.040,95% CI 0.024,0.055)相比,LRAprs 评分明显改善了总体再分类效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Incorporating polygenic risk into the Leicester Risk Assessment score for 10-year risk prediction of type 2 diabetes

Aims

We evaluated whether incorporating information on ethnic background and polygenic risk enhanced the Leicester Risk Assessment (LRA) score for predicting 10-year risk of type 2 diabetes.

Methods

The sample included 202,529 UK Biobank participants aged 40–69 years. We computed the LRA score, and developed two new risk scores using training data (80% sample): LRArev, which incorporated additional information on ethnic background, and LRAprs, which incorporated polygenic risk for type 2 diabetes. We assessed discriminative and reclassification performance in a test set (20% sample). Type 2 diabetes was ascertained using primary care, hospital inpatient and death registry records.

Results

Over 10 years, 7,476 participants developed type 2 diabetes. The Harrell's C indexes were 0.796 (95% Confidence Interval [CI] 0.785, 0.806), 0.802 (95% CI 0.792, 0.813), and 0.829 (95% CI 0.820, 0.839) for the LRA, LRArev and LRAprs scores, respectively. The LRAprs score significantly improved the overall reclassification compared to the LRA (net reclassification index [NRI] = 0.033, 95% CI 0.015, 0.049) and LRArev (NRI = 0.040, 95% CI 0.024, 0.055) scores.

Conclusions

Polygenic risk moderately improved the performance of the existing LRA score for 10-year risk prediction of type 2 diabetes.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
22.90
自引率
2.00%
发文量
248
审稿时长
51 days
期刊介绍: Diabetes and Metabolic Syndrome: Clinical Research and Reviews is the official journal of DiabetesIndia. It aims to provide a global platform for healthcare professionals, diabetes educators, and other stakeholders to submit their research on diabetes care. Types of Publications: Diabetes and Metabolic Syndrome: Clinical Research and Reviews publishes peer-reviewed original articles, reviews, short communications, case reports, letters to the Editor, and expert comments. Reviews and mini-reviews are particularly welcomed for areas within endocrinology undergoing rapid changes.
期刊最新文献
Modifying the timing of breakfast improves postprandial glycaemia in people with type 2 diabetes: A randomised controlled trial Rising trends of diabetes in South Asia: A systematic review and meta-analysis Nanotechnology as a potential treatment for diabetes and its complications: A review Association of dietary manganese intake with new-onset chronic kidney disease in participants with diabetes The effectiveness of delivery modalities of non-pharmacological diabetes prevention programs: A systematic review and component network meta-analysis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1